New Doxorubicin Prodrug for Ovarian Cancer Treatment
Author Information
Author(s): Houba P H J, Boven E, Meulen-Muileman I H van der, Leenders R G G, Scheeren J W, Pinedo H M, Haisma H J
Primary Institution: Department of Medical Oncology, University Hospital Vrije Universiteit
Hypothesis
The novel doxorubicin-glucuronide prodrug DOX-GA3 will show improved efficacy and distribution in treating human ovarian cancer compared to standard doxorubicin.
Conclusion
DOX-GA3 is more effective than standard doxorubicin in inhibiting tumor growth in ovarian cancer models.
Supporting Evidence
- DOX-GA3 showed a 7.6-times lower peak plasma concentration than standard DOX.
- In tumor tissue, DOX-GA3 resulted in a peak concentration of 9.57 nmol g–1, significantly higher than DOX's 2.14 nmol g–1.
- The area under the curve of DOX in tumor tissue was 10-fold higher after DOX-GA3 compared to DOX.
- Maximum tumor growth inhibition was 87% with DOX-GA3 compared to 56% with DOX.
Takeaway
A new medicine called DOX-GA3 works better than an old one for treating a type of cancer by targeting the tumor more effectively.
Methodology
The study involved synthesizing the prodrug DOX-GA3 and testing its pharmacokinetics and anti-tumor effects in nude mice with human ovarian cancer xenografts.
Participant Demographics
Nude mice bearing human ovarian cancer xenografts (OVCAR-3).
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website